中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2010年
2期
143-146
,共4页
樊瑛%杨树森%于江波%郝金红%韩薇%甘润韬%王政%李为民%黄永麟
樊瑛%楊樹森%于江波%郝金紅%韓薇%甘潤韜%王政%李為民%黃永麟
번영%양수삼%우강파%학금홍%한미%감윤도%왕정%리위민%황영린
冠状动脉循环%降血脂药%血流储备分数,心肌
冠狀動脈循環%降血脂藥%血流儲備分數,心肌
관상동맥순배%강혈지약%혈류저비분수,심기
Coronary circulation%Antilipemic agents%Fractional flow reserve,myocardial
目的 探讨冠状动脉血流缓慢患者冠状动脉血流储备(CFR)的改变以及阿托伐他汀对这类患者CFR的影响.方法 入选有胸痛症状但冠状动脉造影结构正常的冠状动脉血流缓慢患者91例,分为治疗组(51例)和无治疗组(40例).治疗组给予阿托伐他汀20 mg治疗8周.另选26例冠状动脉造影正常且运动试验阴性的无心脏疾患者为正常对照组.治疗前后测定治疗组和无治疗组的血脂以及利用腺苷负荷超声记录左前降支远端血流频谱,并评价CFR.结果 (1)冠状动脉血流缓慢者接受阿托伐他汀8周治疗后总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)较无治疗组及正常对照组明显减低[TC:(3.83±0.80)mmol/L比(5.30±1.18)mmol/L和(5.32±1.17)mmol/L,均P<0.05:LDL=C:(2.26±0.64)mmol/L比(3.28±0.85)mmol/L和(3.30±0.82)mmol/L,均P<0.05].(2)给予阿托伐他汀前,治疗组与无治疗组CFR(分别为2.32±0.30和2.25±0.33)均低于正常对照组(3.15±0.34,P<0.05);8周后,治疗组冠状动脉血流速度(CFV)[(26.06±3.22)cm/s]较无治疗组[(29.02±3.36)cm/s]及治疗前静息状态[(28.43±3.40)cm/s]低(均P<0.05),最大冠状动脉扩张状态CFV高于无治疗组和对照组[分别为(77.63±8.96)、(65.17±7.22)和(64.58±6.26)cm/s,P<0.05],CFR低于治疗前和无治疗组(分别为3.07±0.29、2.28±0.35和2.32±0.30,P<0.05),且与正常对照组差异均无统计学意义.结论 冠状动脉血流缓慢患者CFR明显减低,短期阿托伐他汀在调脂的同时可以有效改善其CFR.
目的 探討冠狀動脈血流緩慢患者冠狀動脈血流儲備(CFR)的改變以及阿託伐他汀對這類患者CFR的影響.方法 入選有胸痛癥狀但冠狀動脈造影結構正常的冠狀動脈血流緩慢患者91例,分為治療組(51例)和無治療組(40例).治療組給予阿託伐他汀20 mg治療8週.另選26例冠狀動脈造影正常且運動試驗陰性的無心髒疾患者為正常對照組.治療前後測定治療組和無治療組的血脂以及利用腺苷負荷超聲記錄左前降支遠耑血流頻譜,併評價CFR.結果 (1)冠狀動脈血流緩慢者接受阿託伐他汀8週治療後總膽固醇(TC)和低密度脂蛋白膽固醇(LDL-C)較無治療組及正常對照組明顯減低[TC:(3.83±0.80)mmol/L比(5.30±1.18)mmol/L和(5.32±1.17)mmol/L,均P<0.05:LDL=C:(2.26±0.64)mmol/L比(3.28±0.85)mmol/L和(3.30±0.82)mmol/L,均P<0.05].(2)給予阿託伐他汀前,治療組與無治療組CFR(分彆為2.32±0.30和2.25±0.33)均低于正常對照組(3.15±0.34,P<0.05);8週後,治療組冠狀動脈血流速度(CFV)[(26.06±3.22)cm/s]較無治療組[(29.02±3.36)cm/s]及治療前靜息狀態[(28.43±3.40)cm/s]低(均P<0.05),最大冠狀動脈擴張狀態CFV高于無治療組和對照組[分彆為(77.63±8.96)、(65.17±7.22)和(64.58±6.26)cm/s,P<0.05],CFR低于治療前和無治療組(分彆為3.07±0.29、2.28±0.35和2.32±0.30,P<0.05),且與正常對照組差異均無統計學意義.結論 冠狀動脈血流緩慢患者CFR明顯減低,短期阿託伐他汀在調脂的同時可以有效改善其CFR.
목적 탐토관상동맥혈류완만환자관상동맥혈류저비(CFR)적개변이급아탁벌타정대저류환자CFR적영향.방법 입선유흉통증상단관상동맥조영결구정상적관상동맥혈류완만환자91례,분위치료조(51례)화무치료조(40례).치료조급여아탁벌타정20 mg치료8주.령선26례관상동맥조영정상차운동시험음성적무심장질환자위정상대조조.치료전후측정치료조화무치료조적혈지이급이용선감부하초성기록좌전강지원단혈류빈보,병평개CFR.결과 (1)관상동맥혈류완만자접수아탁벌타정8주치료후총담고순(TC)화저밀도지단백담고순(LDL-C)교무치료조급정상대조조명현감저[TC:(3.83±0.80)mmol/L비(5.30±1.18)mmol/L화(5.32±1.17)mmol/L,균P<0.05:LDL=C:(2.26±0.64)mmol/L비(3.28±0.85)mmol/L화(3.30±0.82)mmol/L,균P<0.05].(2)급여아탁벌타정전,치료조여무치료조CFR(분별위2.32±0.30화2.25±0.33)균저우정상대조조(3.15±0.34,P<0.05);8주후,치료조관상동맥혈류속도(CFV)[(26.06±3.22)cm/s]교무치료조[(29.02±3.36)cm/s]급치료전정식상태[(28.43±3.40)cm/s]저(균P<0.05),최대관상동맥확장상태CFV고우무치료조화대조조[분별위(77.63±8.96)、(65.17±7.22)화(64.58±6.26)cm/s,P<0.05],CFR저우치료전화무치료조(분별위3.07±0.29、2.28±0.35화2.32±0.30,P<0.05),차여정상대조조차이균무통계학의의.결론 관상동맥혈류완만환자CFR명현감저,단기아탁벌타정재조지적동시가이유효개선기CFR.
Objective To investigate the impact of statin use on coronary flow reserce(CFR)in patients with slow coronary flow.Methods A total of 91 patients with chest pain and coronary slow flow but normal coronary angiography were included in this study,patients were divided into statin group(atrovastatin 20 ms/d for 8 weeks,n=51)and non-statin group(n=40),26 healthy subjects with normal angiography and negative exercise ECG test served as normal controls.Blood cholesterol was measured.Doppler coronary flow velocity and Doppler reserve measurement of distal left anterior descending were recorded at rest and adenosine infusion(140 μg·kg~(-1)·min~(-1))induced hyperemia state,CFR was calculated by the ratio of maximal hyperemia and baseline peak diastolic coronary flow velocity(hCFV and bCFV)before and after atrovastatin treatment.Results (1)Eight weeks later,total cholesterol and LDL-C levels were significantly lower in statin group than in non-statin group and control group[TC(3.83±0.80)mmol/L vs.(5.30±1.18)mmol/L vs.(5.32±1.17)mmol/L,P<0.05;LDL-C(2.26±0.64)mmol/L vs.(3.28±0.85)mmoL/L vs.(3.30±0.82)mmol/L,P<0.05].(2)Baseline CFR levels were significantly lower in statin group and non-statin group than that in control group(2.32±0.30 vs.2.25±0.33 vs.3.15±0.34,P<0.05).Compared with non-statin group and statin group before treatment,8 weeks statin treatment was associated with reduced bCFV[(26.06±3.22)cm/s vs.(29.02±3.36)cm/s and(26.06±3.22)cm/svs.(28.43±3.40)cm/s,P<0.05],increased hcFV[(77.63±8.96)cm/s vs.(65.17±7.22)cm/sand(77.63±8.96)cm/s vs.(64.58±6.26)cm/s,P<0.05]and increased CFR(3.07±0.29 vs.2.28±0.35 and 3.07±0.29 vs.2.32±0.30,P<0.05).bCFV,hCFV and CFR of statin group post treatment were similar to those of controls(P>0.05).Conclusion Patients with coronary slow flow were associated with lower CFR which could be significantly improved by statin therapy.